Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antagonist efficacy in MORS196L mutant is affected by the interaction between transmembrane domains of the opioid receptor.

The Journal of pharmacology and experimental therapeutics - 1 Apr 2005

Claude-Geppert Patricia A, Liu Jiahui, Solberg Jonathan, Erickson-Herbrandson Laurie J, Loh Horace H, Law Ping-Yee

Abstract excerpt

In a previous study, we demonstrated that antagonists such as naloxone or naltrexone acted as full agonists at the mu-opioid receptor (MOR)/delta-opioid receptor (DOR) chimeric receptor (mudelta2, where the DOR sequence from the first extracellular loop to the carboxyl terminus was spliced to the MOR sequence) when a conserved serine residue in transmembrane 4 (TM4) was mutated to leucine. However, when Ser196 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Naltrexone
Share to Narcotic Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Radioligand Assay

Share to Receptors, Opioid

Share to Receptors, Opioid, delta

Share to Receptors, Opioid, mu

Share to RNA, Complementary

Share to Xenopus

Source

Identifiers

PMID: 15579496
DOI: 10.1124/jpet.104.076505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antagonist efficacy in MORS196L mutant is affected by the interaction between transmembrane domains of the opioid receptor.PMID 15579496Read ↗

Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists.Semantic proximity Read ↗

Mutational analysis of the structure and function of opioid receptors.Semantic proximity Read ↗

Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.Semantic proximity Read ↗

DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.Semantic proximity Read ↗

Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.Semantic proximity Read ↗

Functional characterization of human variants of the mu-opioid receptor gene.Semantic proximity Read ↗

Molecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI.Semantic proximity Read ↗

Rescuing the traffic-deficient mutants of rat mu-opioid receptors with hydrophobic ligands.Semantic proximity Read ↗

Opioid Addiction and Opioid Receptor Dimerization: Structural Modeling of the OPRD1 and OPRM1 Heterodimer and Its Signaling Pathways.Semantic proximity Read ↗

Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.Semantic proximity Read ↗

Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor.Semantic proximity Read ↗

The local environment at the cytoplasmic end of TM6 of the mu opioid receptor differs from those of rhodopsin and monoamine receptors: introduction of an ionic lock between the cytoplasmic ends of helices 3 and 6 by a L6.30(275)E mutation inactivates the mu opioid receptor and reduces the constitutive activity of its T6.34(279)K mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.